Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Authors
Keywords
Anti–PD-L1, Avelumab, Bladder cancer, Immune checkpoint inhibitor, Immunotherapy, Patient-reported outcomes, Quality of life, Urothelial carcinoma
Journal
EUROPEAN UROLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-31
DOI
10.1016/j.eururo.2022.04.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reliability, validity, and clinically important differences (CIDs) on the NCCN/FACT Bladder Symptom Index (NFBISI-18) among individuals with locally advanced or metastatic urothelial cancer (UC).
- (2021) John Peipert et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- (2021) Thomas Powles et al. LANCET ONCOLOGY
- PCN214 Responsiveness and Responder Definitions for the NCCN/FACT Bladder Symptom Index (NFBISI-18) in Individuals With Locally Advanced or Metastatic Urothelial Cancer (UC)
- (2021) J. Peipert et al. VALUE IN HEALTH
- The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
- (2021) Richard Cathomas et al. EUROPEAN UROLOGY
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2021) T. Powles et al. ANNALS OF ONCOLOGY
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
- (2020) A.S. Mansfield et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Marina C Garassino et al. LANCET ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
- (2020) Gry A. Taarnhøj et al. Cancer Medicine
- 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
- (2020) T.B. Powles et al. ANNALS OF ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review
- (2019) Mieke Van Hemelrijck et al. BMC Urology
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
- (2019) Rina Hui et al. LANCET ONCOLOGY
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Patient-Centered Outcomes in Bladder Cancer
- (2018) John L. Gore Current Urology Reports
- Mental health implications in bladder cancer patients: A review
- (2018) Hannah Pham et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer
- (2012) S. Singer et al. SUPPORTIVE CARE IN CANCER
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Likert scales, levels of measurement and the “laws” of statistics
- (2010) Geoff Norman ADVANCES IN HEALTH SCIENCES EDUCATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More